ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

House committee asks GAO to investigate Klausner-era NCI contract with Harvard University.

September 9, 2005

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

May 2, 2008

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

Cancer Pain Treatment Guide Published By NCCN, ACS

April 27, 2001

NCI To Send Eight To AIDS Conference, Few Will Attend Cancer Meetings

February 28, 1992

NCI to Implement More Transparent Formula For Calculating Cancer Center Support Grants

June 11, 2014